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Background: We have previously shown that galantide, a non-specific galanin receptor antagonist,
ameliorates acute pancreatitis (AP) induced in mice. Octreotide, a somatostatin analogue, has been used
in the treatment of AP with inconsistent outcomes. This study set out to compare the efficacy of a
combined treatment of galantide and octreotide with the efficacy of each agent individually in experi-
mental AP.
Methods: Acute pancreatitis was induced in mice with 7-hourly caerulein injections. Galantide and/or
octreotide were co-administered with each caerulein injection commencing with the first injection. Control
animals received galantide, octreotide or saline alone. Pancreata were harvested for histological exami-
nation and estimation of myeloperoxidase (MPO) activity. Plasma amylase and lipase activities were
measured.
Results: Galantide significantly reduced AP-induced hyperenzymaemia by 39–45%. Octreotide alone,
or in combination with galantide, did not significantly alter AP-induced hyperenzymaemia. Plasma
enzyme activity in the control groups was comparable with pre-treatment activity. Galantide and oct-
reotide administered individually reduced MPO activity by 79% and 50%, respectively; however their
combination was without effect. Galantide, octreotide and their combination significantly reduced the
percentage of abnormal acinar cells by 28–45%.
Conclusions: Treatment with galantide alone ameliorated most of the indices of AP studied, whereas
treatment with octreotide reduced pancreatic MPO activity and acinar cell damage. Combining the two
peptides appears to negate their individual benefits, which suggests an interaction in their mechanism of
action.
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Introduction
Acute pancreatitis (AP) is a disease with high morbidity and mor-
tality and a complex pathophysiology.1 Despite extensive investi-
gation, to date there exists no specific medical treatment for AP.2
Given the numerous factors involved in the pathogenesis of AP, it
appears that successful treatment of this disease may depend upon
combining more than one therapeutic agent and on each agent
targeting apparently different steps in AP. In this study, we inves-
tigated two possible therapeutic agents.
We have previously demonstrated that galanin is involved in the
pathogenesis of caerulein-induced AP in mice and the Australian
possum.3–7 Mice carrying a loss-of-function mutation in the
galanin gene (galaninknockout,GalKO)have less severe caerulein-
inducedAP.5 Galantide, a non-specific galanin receptor antagonist,
is a peptide consisting of fragments of galanin and substance P
(galanin-[1-12]-Pro-substance P-[5-11] amide).8 We and others
have previously shown that galantide is able to antagonize the
effects of galanin on pancreatic function6,8 and to ameliorate
caerulein-induced AP in mice and the Australian possum.3–7
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Octreotide, a somatostatin analogue, has been used clinically as
a treatment for AP.9 However, its beneficial results in AP have been
inconsistent: some studies have shown an improvement in all
parameters studied (plasma enzyme reduction, inflammatory
markers, histological benefit),9–12 whereas others suggest no
benefit at all.13–15 These inconsistencies have been ascribed to the
application of different animal models of AP, different doses of
octreotide and different treatment protocols.
Peptide therapeutics is a growing field16 and the application of
peptides in the treatment of AP has been very limited. Peptides
offer several advantages as therapeutic agents, particularly the
potential for minimal central side-effects.16 Galantide is one of
several galanin receptor antagonists that are chimeric peptides.8
Similarly, octreotide is an octapeptide that mimics somatostatin
pharmacologically.
In this study, we tested the hypothesis that a somatostatin ana-
logue in combination with galantide, delivered at the induction of
AP, would be a more effective treatment for AP than either agent
alone.We aimed to investigate the effects of octreotide alone and in
combination with galantide on the biochemical (plasma amylase
and lipase and pancreatic myeloperoxidase [MPO]) and histolo-
gical indices of AP induced by caerulein hyperstimulation in mice.
Materials and methods
All experiments were approved by the AnimalWelfare Committee
of Flinders University. For these studies we used the caerulein
mouse model originally described by Niederau et al.17 Male Swiss
mice aged 6–8 weeks and weighing 25–30 g were used. The mice
were maintained in a facility with a controlled temperature (21–
24 °C) and lighting (12 : 12 h light : dark cycle). Standard labora-
tory chow and drinking water were provided ad libitum. A
minimum period of 2 days was allowed for animals to acclimatize
before any experimental manipulations were undertaken. Mice
were fasted for 12 h before the induction of AP and had free access
to water.
The mice were allocated to seven groups (Table 1). On the day
prior to AP induction, a blood sample was collected by retro-
orbital sinus bleeding under anaesthesia and used to measure the
basal plasma enzyme activity.3,5,18
Peptide stock solutions were prepared in 0.01% bovine serum
albumin (BSA; Sigma-Aldrich Corp., St Louis, MO, USA) in
saline. On the day of the experiment, AP was induced by seven
intraperitoneal (i.p.) injections of caerulein (50 mg/kg) (American
Peptide Co., Sunnyvale, CA, USA) administered in 150 ml of 0.9%
NaCl at hourly intervals over 0–6 h. Eachmouse was given a single
subcutaneous injection of 100 mg/kg of buprenorphine-HCl
(Temgesic Inject; Reckitt Benckiser Health Care UK, Hull, UK) at
the induction of AP. This dose provided analgesia for the duration
of the experimental period.18
Treatment protocols
Galantide (Bachem AG, Bubendorf, Switzerland) at a dose of
66 mg/kg was co-administered with each injection of caerulein
commencing with the first caerulein injection (Fig. 1). Octreotide
(American Peptide Co.) at a dose of 250 mg/kg was co-
administered with caerulein at hourly intervals over 6 h (for a
total of seven injections). The i.p. injection dose of octreotide
(250 mg/kg) was previously used by Yuan et al. in a caerulein
model of AP in mice.19 In the experiments in which the two
peptides were combined, each peptide, including caerulein, was
administered separately.
Mice were killed 6 h after the final caerulein injection under
anaesthesia as previously described.3,5,18 Each pancreas was then
harvested and divided into two pieces; one piece was placed in
10% buffered formalin solution for subsequent histological
examination and the other piece was quickly blotted on gauze to
remove excess blood and stored at -70 °C for subsequent MPO
extraction and assay.18,20,21 Myeloperoxidase activity was expressed
as IU per mg of protein. The plasma samples were assayed for
amylase and lipase activity using an enzymatic colorimetric
assay (Roche/Hitachi, Roche Diagnostics GmbH, Mannheim,
Germany) using a Roche/Hitachi Modular Analyser (Hitachi
High-Technologies Corp., Tokyo, Japan).
Histological analysis of pancreatic damage
Fixed pancreatic tissue was processed for standard haematoxylin
and eosin histology. The histological analysis was performed
using a point-counting morphometry method as previously
Table 1 Experimental groups: protocols and animal numbers
Group Protocol Mice per group
1 Control, no AP (saline) 4
2 Control, AP 9
3 GT alone 6
4 OT alone 4
5 AP + GT 10
6 AP + OT 9
7 AP + OT + GT 12
AP, acute pancreatitis; GT, galantide (dose = 66 mg/kg/h); OT, octreotide
(dose = 250 mg/kg/h)
Hours
Intraperitoneal caerulein (50 μg/kg in saline)
± GT (66 μg/kg) ± OT (0.25 mg/kg)
or GT alone, OT alone or saline
0 1 2 3 4 5 6 12
Figure 1 Diagram illustrating the treatment protocol for administra-
tion of antagonists. The timeline shows doses of caerulein, galantide
(GT) and octreotide (OT). GT and OT were administered at hourly
intervals for 6 h starting from the first injection of caerulein. Mice
were killed at 12 h
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described.3,18,22 The number of abnormal acinar cells was
expressed as the percentage of total acinar cells counted. Intersti-
tial space was expressed as a proportion of the number of points
counted. Group data were expressed as mean  standard error
(SE) (n = 4–12 mice).
Statistical analysis
Statistical analysis was performed using spss Version 11.5 (SPSS,
Inc., Chicago, IL, USA). The Mann–Whitney U-test was used and
a P-value of <0.05 was regarded as significant.
Results
Plasma enzymes
The induction of AP produced an approximately six-fold increase
in plasma amylase activity and an approximately nine-fold increase
in plasma lipase activity (Fig. 2A, B). Treatment with galantide
reduced the caerulein-induced elevation in plasma amylase and
lipase activities by 39%and45%(P<0.007 andP<0.009 compared
with AP alone), respectively. Neither octreotide alone nor the
combination of galantide and octreotide reduced the caerulein-
induced hyperenzymaemia. Neither agent alone nor saline altered
plasma enzyme activity compared with basal activity.
Pancreatic MPO
The induction of AP resulted in a 28-fold increase in pancreatic
MPO activity compared with saline alone (Fig. 3). Treatment with
galantide or octreotide significantly reduced pancreatic MPO
activity compared with AP alone by 79% and 50% (both P <
0.002), respectively. The reduction in MPO activity by galantide
was significantly greater than that caused by octreotide (P <
0.011). Surprisingly, the combination of the two agents did not
affect MPO activity compared with AP alone. Pancreatic MPO
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Figure 2 Effects of administration of galantide (GT) and octreotide (OT) on acute pancreatitis (AP)-induced (A) hyperamylasaemia and (B)
hyperlipasaemia. A significant increase was noted in plasma amylase activity following the induction of AP. Treatment of AP with GT alone
reduced plasma amylase and lipase activity. Treatment of AP with OT alone and GT + OT had no effect on AP-induced hyperenzymaemia.
Treatment with either GT or OT alone had no effect on plasma enzyme activity.  represents basal enzyme activity for each group;
represents post-treatment enzyme activity. Data are expressed as IU/l and are presented as mean + standard error (n = 4–12). *P < 0.05
compared with the saline group; †P < 0.05 compared with the AP-alone group
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activity in the galantide-alone group was low but significantly
greater (P < 0.011) than that in the saline group, whereas MPO
activity in the octreotide-alone group did not significantly differ
from that in the saline group (Fig. 3).
Pancreatic damage
As expected, histological assessment of pancreatic tissue revealed
abnormal acinar cells and interstitial oedema in the mice with AP
(Figs 4A, B and 5). In the AP-alone group, 63% of the acinar cells
were abnormal (Figs 4A, 5). Treatment with galantide significantly
reduced the percentage of abnormal acinar cells by 34% (P <
0.001) compared with the AP-alone group. Similarly, octreotide
treatment significantly reduced the percentage of abnormal acinar
cells by 45% compared with the AP-alone group (P < 0.001).
Treatment with the combination galantide + octreotide also sig-
nificantly reduced the percentage of abnormal acinar cells by 28%
(P < 0.001); this reduction was significantly less than that caused
by AP treatment with octreotide alone (P < 0.023), but did not
differ from that produced with galantide alone (P < 0.323). The
galantide- or octreotide-alone control groups displayed a minor
but statistically significant increase in the percentage of abnormal
acinar cells compared with the saline group.
Interstitial oedema was increased about three-fold in the
AP-alone group compared with the saline control group (P <
0.005) (Figs 4B, 5). Treatment with octreotide alone significantly
reduced the interstitial oedema compared with AP alone by 29%
(P < 0.04), whereas treatment with galantide alone or the combi-
nation of the two peptides failed to alter the oedema compared
with AP alone.
Discussion
This study demonstrated that treatment of AP with either galan-
tide or octreotide, administered at the induction of AP, reduced
most of the elevated markers of AP measured, including pancre-
atic damage. Interestingly, treatment with the combination of the
two agents was much less effective.
To date there exists no specific treatment forAP.Thismay reflect
the complexity of its pathophysiology, which involves multiple
factors.Another importantdeterminantof the courseof thedisease
which may impact the success of any treatment is the time delay
from the actual onset of the disease to the patient’s presentation to
the hospital.Although 50%of patients present in the first 12 h after
the onset of disease, up to 30%of patientsmay present after 24 h of
symptoms.23Hence any strategy targeting a single agent or pathway
may be insufficient to control the progress of the disease. An
alternative strategy is to targetmultiple steps in the pathogenesis of
the disease by combining more than one therapeutic agent. In this
study, we attempted to explore for the first time the benefit of
administering the two peptides galantide and octreotide (previ-
ously shown individually to ameliorate the indices of AP) at the
induction of AP. The impact of our findings is two-fold: firstly, this
research may provide us with a potential novel therapy in the
prevention of endoscopic retrograde cholangiopancreatography
(ERCP)-induced AP, and, secondly, it provides the impetus for
further experiments exploring the role of the combination in a
delayed setting in AP (a situation that closely mimics the actual
clinical scenario in AP arising from most other causes).
Galantide has been shown to ameliorate caerulein-induced
severe AP in mice and in the Australian possum.3,5–7 Our studies to
date indicate that galanin acts at several steps in the induction and
progression of AP. The present study confirms our previous
reports of the beneficial effects of galantide treatment in a mild
model of AP. In the present study, galantide administered at AP
induction ameliorated most of the indices of AP, except oedema.
The effect of galantide on plasma amylase activity is consistent
with an inhibition of the co-stimulatory/potentiating effect of
galanin on caerulein-stimulated amylase secretion.24
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Figure 3 Effects of administration of galantide (GT) and octreotide (OT) on acute pancreatitis (AP)-induced pancreatic myeloperoxidase
(MPO) activity. Treatment of AP with either GT or OT alone reduced MPO activity compared with the AP-alone group. Treatment of AP with
GT + OT did not reduce MPO activity compared with the AP-alone group. Treatment with GT alone did alter pancreatic MPO activity
compared with the saline group, but treatment with OT alone did not. MPO activity is expressed as IU/mg protein. Data are presented as
mean + standard error (n = 4–12). *P < 0.05 compared with the saline group; †P < 0.05 compared with the AP-alone group
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Ischaemia involving the pancreatic microvasculature is a key
trigger in the progression of pancreatic damage after the onset of
AP.25 Galanin has been shown to induce pancreatic microvascular
vasoconstriction6 and galantide has been shown to be vasodila-
tory, which may prevent the development of pancreatic necrosis.
Moreover, galanin is known to inhibit the secretion of insulin.8
Therefore, it is also possible that galantide, by antagonizing gala-
nin’s inhibition of insulin release, may increase local concentra-
tions of insulin. Insulin is important for the regeneration of acinar
cells following AP26 and potentiates the expression of heat shock
proteins including hsp 70.27,28 Insulin is also known to induce
actin-cytoskeletal reorganization in order to mediate a wide
variety of biological actions, including cell growth, migration and
metabolism.29
A recent study by Schmidhuber et al.30 reported that adult mice
carrying a loss-of-function mutation in the galanin gene (Gal KO)
demonstrated an absence of the normal neurogenic inflammatory
response upon treatment of the skin with either noxious heat or
the vanilloid receptor 1 agonist capsaicin. These and other find-
ings reported by the same authors suggest a role for galanin in
neurogenic inflammation in murine skin.30 Neurogenic inflam-
mation is a contributor to AP.31 Galantide may ameliorate AP by
attenuating neurogenic inflammation by virtue of its antagonism
of galanin’s effects in the pancreas.3
Octreotide, a long-acting somatostatin analogue, has been
extensively studied in relation to AP. The rationale behind the use
of octreotide as a treatment for AP is based on several observa-
tions, including its inhibitory effects on pancreatic exocrine secre-
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Figure 4 Acute pancreatitis (AP)-induced pancreatic damage showing percentages of (A) abnormal pancreatic acinar cells and (B) pancreatic
interstitial oedema in different experimental groups. Induction of AP resulted in a significant increase in the percentage of abnormal acinar
cells. Treatment with galantide (GT) or octreotide (OT), individually and in combination, reduced the percentage of abnormal acinar cells
compared with that in the AP-alone group. The OT- or GT-alone control groups showed a small but statistically significant increase in the
percentage of abnormal pancreatic acinar cells compared with the saline group. The saline group displayed no abnormal pancreatic acinar
cells. Only the treatment with OT significantly reduced pancreatic interstitial oedema compared with AP alone. Oedema in the OT- or
GT-alone control groups did not significantly differ from that in the saline group. Data are presented as mean + standard error (n = 4–12).
*P < 0.05 compared with the saline group; †P < 0.05 compared with the AP-alone group
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tion32 and its ability to reduce the degree of leukocyte infiltration
and focal areas of pancreatic tissue necrosis in experimentally
induced AP.12 Its ability to increase the tone of the sphincter of
Oddi has been used in the prevention and treatment of post-
ERCP pancreatitis, in which it is believed to reduce the reflux of
duodenal contents into the pancreatic duct.33
The effects of octreotide on pancreatic exocrine secretion have
been studied in animals9–15 as well as humans34,35 in terms of its
Figure 5 Representative haematoxylin and eosin stained photomicrographs of pancreatic sections for the various groups. (A) The induction
of acute pancreatitis (AP) resulted in abnormal acinar cells (arrow) and interstitial oedema (*). Co-administration of (B) galantide (GT)
(66 mg/kg), (C) octreotide (OT) (250 mg/kg) or (D) the combination of the two peptides with caerulein (AP + GT + OT) resulted in a significant
reduction in abnormal acinar cells. Normal acinar cell architecture was seen following administration of (E) GT alone (66 mg/kg), (F) OT alone
(250 mg/kg) and (G) saline (SAL). Original magnification ¥40
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potential as a therapeutic agent for AP. The proposed mechanisms
by which octreotide was shown to ameliorate AP in previous
studies included the inhibition of basal and the stimulation of
exocrine pancreatic secretion,36 by which it ‘puts the pancreas to
rest’, reduces the degree of leukocyte infiltration and limits focal
areas of pancreatic tissue necrosis in experimentally induced AP,12
the reduction of lipid peroxidation,37 and the production of his-
tological changes consistent with organization and healing in
established cases of AP.9 However, reports on the action of
somatostatin and octreotide on pancreatic exocrine secretion are
inconsistent and reflect the use of different species and concen-
trations and the complexity of the system under study.9,12,38,39
Our current findings of a lack of effect of octreotide on plasma
enzyme levels in a caerulein model of AP are comparable with
those of previous studies using a similar model.38,39 However, the
mechanisms responsible are unclear. One possible mechanism
could be that offered by Jenkins et al.40 These authors showed that
following the initial inhibition of pancreatic enzyme and overall
juice secretion by octreotide, continued administration of the
drug resulted in a steep increase (‘escape phenomenon’) in the
enzyme level despite a continued inhibition of overall juice secre-
tion within 4–5 h. This ‘escape phenomenon’ may reflect the
desensitization of the somatostatin receptors involved in the regu-
lation of pancreatic amylase secretion. Using a mouse pancreatic
lobule preparation under experimental conditions equivalent to
those used in the present study, we recently showed that galanin
potentiated amylase secretion induced by supramaximal concen-
trations of caerulein and that this response was partly mediated
by endogenous somatostatin, indicating an interaction between
galanin and somatostatin.24 Thus the caerulein-induced release of
endogenous somatostatin may occupy the somatostatin receptors
regulating acinar cell secretion, thereby preventing the binding of
octreotide and consequently resulting in no change in AP-induced
hyperenzymaemia with octreotide treatment. Another explana-
tion may involve the inability of octreotide to overcome cholecys-
tokinin (CCK)-stimulated amylase secretion, as reported by
Garvin et al.41
In the present study we also noted an unexpected reduction in
the efficacy of the agents when used in combination, suggesting
interactions at one or more sites. As outlined above, interactions
between galanin and somatostatin can occur in the presence of
supramaximal concentrations of caerulein. Another explanation
may relate to the reported potentiation of CCK-stimulated
amylase secretion by somatostatin,42 which could mask or negate
the effect of galantide and result in no significant change in hyper-
enzymaemia. Further studies are required to understand this
unexpected result.
The lack of effect of the combination of these peptides on
pancreatic MPO activity suggests opposing mechanisms of action,
a proposal that is difficult to reconcile. These actions may occur
at the neutrophil recruitment level and/or at the cellular/
intracellular level to modulate the neutrophil activation state, and
hence MPO activity, of the infiltrating neutrophils. As described
above, Schmidhuber et al.,30 found that galanin is involved in neu-
rogenic inflammation caused by substance P. Galantide contains
moieties of galanin and substance P8 and could thus exert its effect
of reducing MPO activity by a mechanism involving either
galanin and/or substance P. Somatostatin has been shown to block
substance P receptors43 and consequently may possibly prevent
galantide from binding to these receptors and exerting its benefi-
cial effects (via substance P antagonism). This may be an example
of common receptor activity of these two peptides. Another
reason for the decreased reduction in MPO activity seen with
octreotide as well as with the combination of the two peptides
may involve the contribution to MPO activity of activated mono-
cytes and macrophages44 as octreotide has been shown to promote
activation of the monocyte–macrophage system.45,46 Octreotide
has also been shown to inhibit neutrophil chemotaxis induced by
substance P.43
Our finding that the combination of the two peptides admin-
istered at the induction of AP has no benefit does not support
further testing of the combination in a delayed setting (i.e. after
the induction of AP).
Conclusions
This study is the first to explore the efficacy of a combination of
two peptides, galantide and octreotide, in the treatment of mild
caerulein-induced AP in mice. From this study we conclude
that treatment with galantide alone ameliorates mild caerulein-
induced AP, whereas treatment with octreotide alone reduces pan-
creatic MPO activity and acinar cell damage. The combination of
the two peptides appears to negate the individual benefits of the
two agents, which may indicate complex interaction(s) in the
mechanism of action of the two peptides at several sites.
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